指南与共识支持与姑息治疗

肿瘤治疗全程心脏疾病管理:ESMO共识推荐

Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations.
指南 / 共识 · Ann Oncol · 2020-01-01

本文为ESMO共识文章,定义癌症或其治疗相关的心血管毒性,并提供预防、筛查、监测和治疗的指导。多数抗癌治疗伴有一定心血管毒性,从无症状一过性到临床显著持久事件不等;需权衡心血管损伤与抗癌获益,个体化治疗。

要点

  • 抗癌治疗可致广谱短期和长期心脏毒性效应
  • 需权衡心血管损伤风险与抗癌治疗获益包括总生存获益
  • 心血管疾病管理需个体化,医生临床判断仍极重要

核心结论

  • 多数抗癌治疗伴有一定心血管毒性,范围从无症状一过性到临床显著持久事件。
  • 关注抗癌治疗潜在心血管损伤时须权衡抗癌治疗获益包括总生存获益。
  • 癌症患者心血管疾病复杂,治疗需个体化。

研究设计与样本

  • ESMO共识文章,旨在定义癌症或其治疗相关心血管毒性并提供管理指导。
  • 本文提出预防、筛查、监测和治疗心血管毒性的建议策略。

主要发现

  • 抗癌治疗可导致广谱短期和长期心脏毒性效应。
  • 新型抗癌治疗除心力衰竭外还引入意外心血管并发症。

临床怎么用

  • 管理策略预计适用于多数患者,但医生临床判断仍极重要。
  • 使用最佳临床实践指导治疗选择和决策时应个案考虑患者个体情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cancer and cardiovascular (CV) disease are the most prevalent diseases in the developed world. Evidence increasingly shows that these conditions are interlinked through common risk factors, coincident in an ageing population, and are connected biologically through some deleterious effects of anticancer treatment on CV health. Anticancer therapies can cause a wide spectrum of short- and long-term cardiotoxic effects. An explosion of novel cancer therapies has revolutionised this field and dramatically altered cancer prognosis. Nevertheless, these new therapies have introduced unexpected CV complications beyond heart failure. Common CV toxicities related to cancer therapy are defined, along with suggested strategies for prevention, detection and treatment. This ESMO consensus article proposes to define CV toxicities related to cancer or its therapies and provide guidance regarding prevention, screening, monitoring and treatment of CV toxicity. The majority of anticancer therapies are associated with some CV toxicity, ranging from asymptomatic and transient to more clinically significant and long-lasting cardiac events. It is critical however, that concerns about potential CV damage resulting from anticancer therapies should be weighed against the potential benefits of cancer therapy, including benefits in overall survival. CV disease in patients with cancer is complex and treatment needs to be individualised. The scope of cardio-oncology is wide and includes prevention, detection, monitoring and treatment of CV toxicity related to cancer therapy, and also ensuring the safe development of future novel cancer treatments that minimise the impact on CV health. It is anticipated that the management strategies discussed herein will be suitable for the majority of patients. Nonetheless, the clinical judgment of physicians remains extremely important; hence, when using these best clinical practices to inform treatment options and decisions, practitioners should also consider the individual circumstances of their patients on a case-by-case basis.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Curigliano G, Lenihan D, Fradley M, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020. PMID: 31959335. doi:10.1016/j.annonc.2019.10.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。